Blasenbildende Autoimmunerkrankungen der Haut – diagnostische und therapeutische Aspekte

Schlüsselwörter

blasenbildende Autoimmundermatosen - Autoantikörper - Pemphigusgruppe - Pemphigoidgruppe

Keywords

autoimmune blistering skin diseases - autoantibodies - pemphigus diseases - pemphigoid diseases

• Literatur

• 1 Amagai M, Ikeda S, Shimizu H et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603
• 2 Behzad M, Mobs C, Kneisel A et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166: 844-852
• 3 Beissert S, Mimouni D, Kanwar AJ et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041-2048
• 4 Goletz S, Hashimoto T, Zillikens D et al. Anti-p200 pemphigoid. J Am Acad Dermatol 2014; DOI: 10.1016/j.jaad.2014.02.036.
• 5 Hammers CM, Lunardon L, Schmidt E et al. Contemporary management of pemphigus. Expert Opin Orphan Drugs 2013; 1: 295-314
• 6 Hertl M, Jedlickova H, Karpati S et al. Pemphigus. S2 Guideline for diagnosis and treatment. . Accessible online at 2013. http://www.euroderm.org/images/stories/guidelines/Autoimmune-bullous-diseases-Pemphigus-S2a.pdf
• 7 Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-552
• 8 Joly P, Roujeau JC, Benichou J et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-327
• 9 Kasperkiewicz M, Shimanovich I, Meier M et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012; 166: 154-160
• 10 Kirtschig G, Middleton P, Bennett C et al. Interventions for bullous pemphigoid. Cochrane Database Systematic Rev 2010; CD002292
• 11 Kneisel A, Hertl M. Blasenbildende Autoimmundermatosen. Teil 2: Diagnostik und Therapie. J Dtsch Dermatol Ges 2011; 9: 927-947
• 12 Lunardon L, Tsai KJ, Propert KJ et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 2012; 148: 1031-1036
• 13 Martin LK, Werth V, Villanueva E et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; CD006263
• 14 Meyersburg D, Schmidt E, Kasperkiewicz M et al. Immunoadsorption in dermatology. Ther Apher Dial 2012; 16: 311-320
• 15 Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046
• 16 Payne AS, Hanakawa Y, Amagai M et al. Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol 2004; 16: 536-543
• 17 Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-691
• 18 Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Artzebl Int 2011; 108: 399-405, I-III
• 19 Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241-253
• 20 Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmunity reviews 2010; 10: 84-89 DOI: 10.1016/j.autrev.2010.08.007.
• 21 Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332
• 22 Schulze F, Kasperkiewicz M, Zillikens D et al. [Bullous pemphigoid]. Hautarzt 2013; 64: 931-943
• 23 van Beek N, Knuth-Rehr D, Altmeyer P et al. Diagnostik blasenbildender Autoimmundermatosen an deutschen Hautkliniken. J Dtsch Dermatol Ges 2012; 10: 492-499
• 24 van Beek N, Rentzsch K, Probst C et al. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012; 7: 49